Invictus RG acquired a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 5,822 shares of the company’s stock, valued at approximately $268,000.
Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. grew its stake in Myriad Genetics by 3.5% during the third quarter. BlackRock Inc. now owns 11,466,610 shares of the company’s stock valued at $527,464,000 after acquiring an additional 383,089 shares in the last quarter. Baillie Gifford & Co. grew its stake in Myriad Genetics by 1.0% during the third quarter. Baillie Gifford & Co. now owns 9,547,193 shares of the company’s stock valued at $439,171,000 after acquiring an additional 92,008 shares in the last quarter. Frontier Capital Management Co. LLC grew its stake in Myriad Genetics by 8.4% during the third quarter. Frontier Capital Management Co. LLC now owns 2,575,754 shares of the company’s stock valued at $118,485,000 after acquiring an additional 198,819 shares in the last quarter. Acadian Asset Management LLC grew its stake in Myriad Genetics by 2.6% during the third quarter. Acadian Asset Management LLC now owns 2,387,166 shares of the company’s stock valued at $109,812,000 after acquiring an additional 59,446 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Myriad Genetics by 2.7% during the second quarter. Northern Trust Corp now owns 1,801,882 shares of the company’s stock valued at $67,337,000 after acquiring an additional 47,994 shares in the last quarter. Hedge funds and other institutional investors own 99.80% of the company’s stock.
Several research firms recently weighed in on MYGN. BidaskClub cut shares of Myriad Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday. Goldman Sachs Group raised shares of Myriad Genetics from a “sell” rating to a “neutral” rating and raised their target price for the company from $28.00 to $32.00 in a research note on Friday, November 30th. TheStreet cut shares of Myriad Genetics from a “b” rating to a “c” rating in a research note on Thursday, November 8th. ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, November 8th. Finally, Deutsche Bank raised their target price on shares of Myriad Genetics from $37.00 to $43.00 and gave the company a “hold” rating in a research note on Monday, November 5th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $41.90.
Shares of NASDAQ:MYGN opened at $31.51 on Friday. Myriad Genetics, Inc. has a 52 week low of $27.27 and a 52 week high of $50.44. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of 23.80, a price-to-earnings-growth ratio of 1.86 and a beta of 0.36. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.17 and a quick ratio of 2.83.
Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, November 6th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.13. Myriad Genetics had a net margin of 7.07% and a return on equity of 10.07%. The business had revenue of $202.30 million during the quarter, compared to analysts’ expectations of $203.20 million. During the same period last year, the company posted $0.26 EPS. The business’s revenue was up 13.1% on a year-over-year basis. As a group, research analysts expect that Myriad Genetics, Inc. will post 1.5 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/12/08/5822-shares-in-myriad-genetics-inc-mygn-acquired-by-invictus-rg.html.
Myriad Genetics Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Featured Article: What is the Coverage Ratio?
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.